Bristol-Myers Squibb, which is set to buy biotechnology company Celgene Corp soon for $74 billion, posted better-than-expected second-quarter earnings on Thursday on strong sales from its blood ...

Nov 16 (Reuters) - Eliquis, a promising blood clot preventer from Bristol-Myers Squibb and Pfizer, has a decent chance at getting an accelerated review by U.S. health regulators in coming months ...